Adamas Pharmaceuticals
ADMS
ADMS was delisted on the 23rd of November, 2021.
79 hedge funds and large institutions have $62.1M invested in Adamas Pharmaceuticals in 2019 Q4 according to their latest regulatory filings, with 12 funds opening new positions, 31 increasing their positions, 19 reducing their positions, and 19 closing their positions.
214% more call options, than puts
Call options by funds: $1.41M | Put options by funds: $449K
63% more repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 19
9% less funds holding
Funds holding: 87 → 79 (-8)
16% less capital invested
Capital invested by funds: $74.3M → $62.1M (-$12.2M)
37% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 19
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$7.95M |
| 2 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$7.13M |
| 3 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
+$1.3M |
| 4 |
Nuveen
Charlotte,
North Carolina
|
+$1.16M |
| 5 |
Renaissance Technologies
New York
|
+$810K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Ameriprise
Minneapolis,
Minnesota
|
-$3.6M |
| 2 |
BlackRock
New York
|
-$2.3M |
| 3 |
KA
Kerrisdale Advisers
Miami,
Florida
|
-$1.17M |
| 4 |
HVC
Healthcare Value Capital
Woodcliff Lake,
New Jersey
|
-$957K |
| 5 |
DAM
Deltec Asset Management
New York
|
-$844K |
ADMS Hedge Fund Activity: Q4 2019 in Review
79 of the 5,092 institutional investors tracked by Wall St. Rank reported a position in Adamas Pharmaceuticals (ADMS) for Q4 2019, worth a combined $62.1M — down 16% from $74.3M a quarter earlier.
Sellers outnumbered buyers: 19 funds closed out of ADMS and 12 opened new positions — a net loss of 7 holders — while 19 trimmed existing stakes and 31 added.
The largest buyer was Armistice Capital, adding an estimated $7.95M. The largest seller was Ameriprise, cutting an estimated $3.6M.
- 79 institutional investors held Adamas Pharmaceuticals (ADMS) as of Q4 2019, down from 87 in Q3 2019.
- Funds reported $62.1M of Adamas Pharmaceuticals stock for Q4 2019, down 16% quarter-over-quarter.
- 12 funds opened new Adamas Pharmaceuticals positions in Q4 2019 and 19 closed out, a net change of -7 holders.
- The largest Adamas Pharmaceuticals buyer in Q4 2019 was Armistice Capital, an estimated $7.95M added.
- The largest Adamas Pharmaceuticals seller in Q4 2019 was Ameriprise, an estimated $3.6M sold.
Based on aggregated 13F filings for Q4 2019.